CRIXIVAN CAPSULE

Država: Kanada

Jezik: engleski

Izvor: Health Canada

Aktivni sastojci:

INDINAVIR (INDINAVIR SULFATE)

Dostupno od:

MERCK CANADA INC

ATC koda:

J05AE02

INN (International ime):

INDINAVIR

Doziranje:

300MG

Farmaceutski oblik:

CAPSULE

Sastav:

INDINAVIR (INDINAVIR SULFATE) 300MG

Administracija rute:

ORAL

Jedinice u paketu:

100

Tip recepta:

Prescription

Područje terapije:

HIV PROTEASE INHIBITORS

Proizvod sažetak:

Active ingredient group (AIG) number: 0133330004; AHFS:

Status autorizacije:

CANCELLED PRE MARKET

Datum autorizacije:

2016-11-01

Svojstava lijeka

_ _
_Product Monograph - CRIXIVAN_
_®_
_ _
_Page 1 of 45_
PRODUCT MONOGRAPH
PR
CRIXIVAN
®
indinavir sulfate capsules
100, 200, 300, and 400 mg
(as indinavir)
HIV Protease Inhibitor
MERCK FROSST CANADA LTD.
16711 Trans Canada Highway
KIRKLAND QC H9H 3L1
Canada
www.merckfrosst.com
Date of Revision:
February 13, 2007
SUBMISSION CONTROL NO: 110356
CRIXIVAN is a
®
Registered Trademark of Merck & Co., Inc.
Used under licence.
_ _
_Product Monograph - CRIXIVAN_
_®_
_ _
_Page 2 of 45_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 3
SUMMARY PRODUCT
INFORMATION........................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................
3
CONTRAINDICATIONS...................................................................................................
3
WARNINGS AND PRECAUTIONS
.................................................................................
4
ADVERSE
REACTIONS...................................................................................................
8
DRUG INTERACTIONS
.................................................................................................
14
DOSAGE AND ADMINISTRATION
.............................................................................
20
OVERDOSAGE................................................................................................................
22
ACTION AND CLINICAL
PHARMACOLOGY............................................................
22
STORAGE AND STABILITY
.........................................................................................
25
DOSAGE FORMS, COMPOSITION AND
PACKAGING............................................. 26
PART II: SCIENTIFIC INFORMATION
..............................................................................
27
PHARMACEUTICAL
INFORMATION.........................................................................
27
CLINICAL TRIALS
...